LPOXY Therapeutics

LPOXY Therapeutics, Inc.Founded in 2020, LPOXY Therapeutics, Inc. specializes in therapeutic innovations for antibiotic-related infections. The company has engaged in a pivotal strategy to enhance its operational focus on SIDIPREV™, a preventive oral medication.LPOXY Therapeutics is primarily focused on the development of SIDIPREV™, an innovative oral medication designed to prevent antibiotic-induced Clostridioides difficile (C. difficile) colitis. This clinical-stage therapy aims to address the urgent public health challenge posed by this superinfection by increasing oxygen tension in the colon during antibiotic treatment. Targeting patients undergoing antibiotic therapy and those with inflammatory bowel diseases, SIDIPREV™ is positioned as a preventative measure in healthcare settings, particularly in the US, where C.LPOXY Therapeutics generates revenue through strategic partnerships and potential distribution agreements for SIDIPREV™. The company aims to collaborate with healthcare providers and pharmaceutical distributors to ensure access to its therapeutic product, utilizing a business-to-business model for wider distribution.In September 2025, LPOXY Therapeutics, Inc. Additionally, LPOXY Therapeutics is focusing on enhancing its product offerings and expanding its market presence, although specific new products or geographic regions targeted for expansion have not been detailed.

1. Series A

   Sep 8, 2025

   Amount

   $28M

   Investors

   Locked